Steven Woods, MD
Critical Care Medicine · Memphis, TNNPI 1215371570
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,402 of the $6,112 with a category attached, or 72.0%. 30 manufacturers reported payments, led by Covidien LP at 35.6% of the total. Reporting peaked in 2020 at $2,362 and has fallen 55.3% since, to $1,056 in 2025.
Across 193 payments — averaging $31.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$2K
- AstraZeneca$1K
- GSK$538
- Harmony Biosciences LLC$255
- Boehringer Ingelheim$252
- Sanofi$176
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,69228%
- Food & beverage$4,40272%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 11 | $2,178 |
| AstraZeneca | 41 | $1,187 |
| GSK | 44 | $538 |
| Harmony Biosciences LLC | 11 | $255 |
| Boehringer Ingelheim | 10 | $252 |
| Sanofi | 8 | $176 |
| Lungpacer Medical USA Inc | 1 | $174 |
| Regeneron Healthcare Solutions, Inc. | 7 | $171 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| AbbVie(2 entities) | 8 | $118 |
| United Therapeutics Corporation | 6 | $109 |
| Merck | 5 | $101 |
| Olympus America Inc. | 1 | $88 |
| Verona Pharma, Inc. | 5 | $83 |
| Veran Medical Technologies, Inc. | 3 | $82 |
| Grifols USA, LLC | 4 | $64 |
| Mylan Specialty L.p. | 5 | $64 |
| Genentech USA, Inc. | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Tactile Systems Technology Inc | 1 | $36 |
| Lilly USA, LLC | 2 | $34 |
| Amgen | 2 | $34 |
| Viatris Specialty LLC | 2 | $31 |
| La Jolla Pharmaceutical Company | 2 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Gilead | 1 | $14 |
| Bayer | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$1,769
- AEROPACE NEUROSTIMULATION CONSOLE$174
- FASENRA$132
- OPDIVO$120
- OFEV$114
- BREZTRI$112
How this compares
$6,112 in reported general payments places this provider in the 80th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $172,455 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 138 | $117,073 |
| XolairOmalizumab | 13 | $75,662 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $41,554 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $20,974 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $19,194 |
| Spiriva RespimatTiotropium Bromide | 24 | $17,269 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $8,079 |
| Tiotropium Bromide | 14 | $6,921 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,556 |
| EliquisApixaban | 35 | $4,897 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $4,726 |
| Mycophenolate Mofetil | 11 | $3,542 |
| EntrestoSacubitril/Valsartan | 20 | $3,376 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $3,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $252 | $195,28149 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $538 | $157,241219 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,187 | $49,63366 claims |
| NovartisEntresto | $16 | $3,37620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Memphis
- Anthony MattoxMemphis$33K
- Nathan WildsMemphis$19K
- Robert AguillardMemphis$11K
- Kimberly MarshMemphis$11K
- Paul DeatonMemphis$10K
- Garrettson EllisMemphis$9K
- Roy FoxMemphis$9K
- Matthew MabieMemphis$7K
- William RichardsMemphis$6K
- Michael MundayMemphis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.